17:51 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

BlackThorn deprioritizing MDD compound after Phase IIa miss

BlackThorn Therapeutics Inc. (San Francisco, Calif.) said it will deprioritize development of BTRX-246040 (formerly LY-2940094) to treat major depressive disorder (MDD) after the compound missed the primary and secondary endpoints in a Phase IIa trial....
00:10 , Nov 9, 2018 |  BioCentury  |  Finance

Biomatics’ next phase

Biomatics Capital plans to take a more active role in company formation and seek more neuroscience investments with its second fund, and has brought on two partners to implement its strategy. With Fund II, which...
00:05 , Nov 6, 2018 |  BC Extra  |  Company News

Management tracks: Audentes, Veloxis

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) appointed CEO and co-founder Matthew Patterson as chairman. Patterson has been a board member since 2012. Audentes also appointed board member Louis Lange as lead independent director. Lange...
22:44 , Sep 13, 2018 |  BC Week In Review  |  Company News

AI healthcare companies forming an alliance

Artificial intelligence healthcare companies are forming an alliance to advance and guide the use of AI in healthcare and drug development. The Alliance for Artificial Intelligence in Healthcare (AAIH) will act as the industry's advocate...
22:37 , Sep 12, 2018 |  BC Extra  |  Politics & Policy

AI healthcare companies forming an alliance

Artificial intelligence healthcare companies are forming an alliance to advance and guide the use of AI in healthcare and drug development. The Alliance for Artificial Intelligence in Healthcare (AAIH) will act as the industry's advocate...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
06:11 , Aug 10, 2018 |  BC Week In Review  |  Company News

BlackThorn licenses Yale's neuroimaging tech

Neurobehavioral disorder company BlackThorn Therapeutics Inc. (San Francisco, Calif.) exclusively licensed neuroimaging technology from Yale University School of Medicine designed to link gene expression patterns with behavioral circuits in the brain. Yale has dubbed the...
23:38 , Aug 6, 2018 |  BC Extra  |  Company News

BlackThorn licenses Yale's neuroimaging drug discovery tech

Neurobehavioral disorder company BlackThorn Therapeutics Inc. (San Francisco, Calif.) exclusively licensed neuroimaging technology from Yale University School of Medicine designed to link gene expression patterns with behavioral circuits in the brain. Yale has dubbed the...
00:55 , Jun 23, 2018 |  BioCentury  |  Emerging Company Profile

Cerevance’s human element

Cerevance Inc. plans to treat neurological diseases by rebalancing disrupted neuronal circuits. The company is identifying circuit-specific neurological targets via its NETSeq RNA profiling platform, and thinks its ability to start with human tissue will...
19:19 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

BlackThorn brings KOR antagonist into clinic

BlackThorn Therapeutics Inc. (San Francisco, Calif.) began a Phase I trial evaluating up to seven single and multiple ascending doses of BTRX-335140 to assess dose exposure and safety in about 90 healthy volunteers. The company...